VAccination in Early and ADvanced Prostate caNCEr

NCT03815942 | Terminated Phase 1 Results DMC

• 1 other identifier: ADVANCE
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 2

Brief Summary

This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer. A vaccine that could alert the immune system to the presence of cancer cells in the body may enable the immune system to target and kill those cells effectively. This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells. The vaccine is made up of two recombinant viruses ("ChAdOx1"- chimpanzee adenovirus Ox1 and "MVA" - modified vaccinia Ankara) that have been designed to produce the 5T4 protein and have been modified so that they are weakened and cannot reproduce themselves within the body like normal viruses. Once injected into the body, these viruses make the 5T4 protein and help the body's immune system to learn to target this protein and destroy cancer cells. This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody. This is a molecule that releases the brakes on the immune system and helps the immune system to kill cancer cells more efficiently. Nivolumab as a monotherapy was approved for treatment of several tumour types but not for the prostate cancer. This study will evaluate the safety and efficacy of ChAdOx1-MVA 5T4 vaccine in combination with nivolumab in low and intermediate risk prostate cancer patients who have elected to have their prostate removed and in patients with advanced metastatic prostate cancer.

Conditions

Intermediate Risk Prostate Cancer; Castration-resistant Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Safety - Incidence of Treatment-related Adverse Events.

  Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. Note: All participants had one or more adverse events during the period they were monitored.

  From baseline to 12 months

• Efficacy - Measure Composite Response Rate Defined as One of the Following: 1) Change in Circulating Tumour DNA 2) Change in Serum PSA

  Evaluate the efficacy by assessing the number of participants with 50% or more change in ctDNA or PSA concentration in the blood from baseline to 12 months post treatment. Change in serum PSA was analysed for this outcome as one the two alternative methods planned. As described in the trial overview, no ctDNA analysis was done due to the trial closing prematurely because of COVID-19 - by the time the pandemic had finished, the facility to perform the ctDNA analysis option was no longer available. Because no laboratory analysis was done, there is no data to report.

  From baseline to 12 months

Secondary Outcomes (4)

• Evaluate Immune Responses to the Vaccine Antigen in the Periphery

  From baseline to 12 months

• Evaluate Immune Cell Subsets in the Prostate Secondary to Treatment (for Surgical Cohort)

  From baseline to radical prostatectomy, an expected average of 6 weeks

• Evaluate Progression-free Survival Following Study Treatment (for Advanced Metastatic Cancer Cohort)

  6-12 months

• Evaluate Overall Survival Following Study Treatment (for Advanced Metastatic Cancer Cohort)

  6-12 months

Study Arms (2)

Intermediate risk prostate cancer

EXPERIMENTAL

ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.

Biological: ChAdOx1-MVA 5T4 vaccine; Drug: Nivolumab Infusion [Opdivo]

Advanced metastatic prostate cancer

EXPERIMENTAL

ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.

Biological: ChAdOx1-MVA 5T4 vaccine; Drug: Nivolumab Infusion [Opdivo]

Interventions

ChAdOx1-MVA 5T4 vaccine BIOLOGICAL

ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units

Advanced metastatic prostate cancer; Intermediate risk prostate cancer

Nivolumab Infusion [Opdivo] DRUG

Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion

Also known as: anti-PD-1 monoclonal antibody

Advanced metastatic prostate cancer; Intermediate risk prostate cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For all participants:
• Histologically confirmed adenocarcinoma of the prostate cancer
• Any antineoplastic therapy must have been completed a minimum of 28 days prior to enrolment
• Systemic antimicrobial therapy must have been completed a minimum of 7 days prior to enrolment
• An archival specimen of tumour tissue should be available
• Baseline laboratory parameters must meet the following criteria:
• Haemoglobin ≥ 80 g/L, White cell count ≥ 2.0 x10\^9/L, Neutrophils ≥ 1.5 x10\^9/L, Lymphocytes ≥ 0.5 x10\^9/L, Platelets ≥ 100 x10\^9/L, Creatinine Clearance ≥ 40 ml/min by Cockcroft Gault formulation, Total Bilirubin ≤ 1.5 ULN, Alanine Aminotransferase ≤ 1.5 ULN, Amylase ≤ 1.5 ULN
• For surgical cohort:
• Clinically localised or locally advanced disease deemed operable by the treating consultant urological surgeon i.e.: Gleason score ≤ 7, local tumour stage ≤T3c and deemed operable, no evidence of metastases (Nx/N0 and Mx/M0), no evidence of high grade Gleason 5 disease, PSA ≤ 20 ng/ml
• Scheduled for and considered fit for radical prostatectomy
• For advanced metastatic cohort:
• Evidence of at least one distant metastasis based on MRI, CT, PET or bone scintigraphy
• Established on and suitable to continue with androgen deprivation therapy (ADT) using any luteinizing hormone releasing hormone (LHRH) agonist
• On treatment with anti-androgen therapy using either abiraterone (Zytiga®) or enzalutamide (Xtandi®) and demonstrating evidence of disease progression at the time of enrolment
• Suitable to continue therapy with either abiraterone or enzalutamide at the time of enrolment at discretion of their managing clinician

You may not qualify if:

• For all participants:
• Any prior diagnosis or clinical suspicion of autoimmune disease
• History of allergic disease or reaction likely to be exacerbated by any component of the vaccine, e.g. egg products
• Other prior malignancy with an estimated ≥ 30% chance of relapse within 2 years
• Participation in another research study involving an investigational product or investigational surgical procedure in the 30 days preceding enrolment, or planned use during the study period
• Any prior exposure to checkpoint inhibitor drugs including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monoclonal antibodies or any prior treatment with investigational vaccines
• Administration of immunoglobulins and/or any blood products within the one month preceding the planned administration of the study drugs
• Seropositive for hepatitis B surface antigen (HBsAg)
• Seropositive for hepatitis C virus (antibodies to HCV)
• Any confirmed or suspected immunocompromised state
• Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema
• History of anaphylaxis in relation to vaccination or any clinically significant allergic disease likely to be exacerbated by any component of the vaccine or checkpoint inhibitor preparations
• For advanced metastatic cohort:
• The treating oncologist estimates a subject's life expectancy to be ≤ 6 months
• Any active, previously treated, or suspected intracranial or leptomeningeal metastases

Sponsors & Collaborators

• University of Oxford: lead
• Barinthus Biotherapeutics: collaborator

Study Sites (2)

Department of Oncology, The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom

Location

Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 7LE, United Kingdom

Location

MeSH Terms

Interventions

Nivolumab; spartalizumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Limitations and Caveats

The trial finished prematurely due to the COVID-19 pandemic in 2020.

Results Point of Contact

• Title: Dr Mark Tuthil
• Organization: University of Oxford

mark.tuthill@oncology.ox.ac.uk

01865 227042

Study Officials

• Adrian VS Hill

  University of Oxford

  STUDY DIRECTOR

• Freddie Hamdy

  Nuffield Department of Surgical Sciences, Oxford University Hospitals NHS Foundation Trust

  STUDY DIRECTOR

• Andrew Protheroe

  Nuffield Department of Surgical Sciences, Oxford University Hospitals NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

• Peter Hoskin

  Department of Oncology, The Christie NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

• Mark Tuthill

  Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2019
• First Posted: January 24, 2019
• Study Start: December 10, 2018
• Primary Completion: June 24, 2020
• Study Completion: June 24, 2020
• Last Updated: June 25, 2025
• Results First Posted: June 25, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (2)